Mode
Text Size
Log in / Sign up
N/A N=1,157 Randomized Double-blind Treatment

Behavior, Biology and Well-Being Study

Depression · Psychological Distress

Enrolled (actual)
1,157
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Depression Symptoms Measured by Patient Health Questionnaire - 8 (PHQ-8) Score — 10.06; 9.85; 9.79; 9.17 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Healthy Minds Program (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Wisconsin, Madison
Primary completion
Jul 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Depression Symptoms Measured by Patient Health Questionnaire - 8 (PHQ-8) Score
10.06; 9.85; 9.79; 9.17; 8.8; 9.45
SECONDARY
Anxiety Symptoms Measured by Generalized Anxiety Disorder - 7 (GAD-7) Score
8.94; 8.67; 8.37; 8.58; 8.13; 8.04
SECONDARY
Sleep Disturbance Measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Score
57.73; 56.94; 56.9; 56.26; 55.91; 57.12
SECONDARY
Flourishing Measured by the Flourishing Index Score
56.26; 56.55; 56.63; 57.19; 57.52; 57.22
SECONDARY
Awareness Measured by Five Facet Mindfulness Questionnaire Acting With Awareness Subscale Score
24.11; 24.41; 23.95; 23.61; 24.26; 24.27
SECONDARY
Connection Measured by NIH Toolbox Loneliness Score
15.1; 14.74; 15.13; 14.33; 13.97; 14.57
SECONDARY
Decentering Measured by Decentering Subscale of Experiencing Questionnaire Scale Score
33.12; 33.22; 33.51; 34.15; 33.92; 33.99
SECONDARY
Meaning in Life Measured by NIH Toolbox Meaning and Purpose Score
43.44; 43.09; 43.33; 42.89; 42.59; 41.58
SECONDARY
Pain Intensity Measured by PROMIS Pain Intensity Score
3.22; 3.33; 3.42; 2.98; 3.12; 3.5
SECONDARY
Pain Interference Measured by PROMIS Pain Inference Scale Score
52.94; 53.6; 53.57; 51.65; 51.66; 53.16
SECONDARY
Nonjudgment Measured by Five Facet Mindfulness Questionnaire Nonjudgment Subscale Score
24.62; 24.35; 23.92; 26.24; 26.32; 25.84
SECONDARY
Climate Change Anxiety Scale
21.17; 20.98; 21.22; 20.79; 20.67; 21.01
SECONDARY
Wellbeing Growth Mindset
14.27; 14.07; 13.88; 14.61; 14.46; 13.50
SECONDARY
Healthy Minds Index (HM Index) - Awareness
9.13; 9.11; 9.01; 9.55; 9.33; 8.72
SECONDARY
Healthy Minds Index (HM Index) - Connection
15.67; 15.65; 15.64; 16.03; 16.16; 15.16
SECONDARY
Healthy Minds Index (HM Index) - Insight
5.79; 5.76; 6.03; 6.78; 6.71; 6.07
SECONDARY
Healthy Minds Index (HM Index) - Purpose
9.07; 8.8; 9.22; 10.19; 10.05; 8.95
SECONDARY
Life Orientation Test - Revised
11.78; 11.71; 11.77; 13.42; 13.01; 12.23
SECONDARY
Perceived Stress Scale
29.7; 29.51; 29.72; 26.46; 26.90; 29.17
SECONDARY
Perseverative Thinking Questionnaire
32.02; 31.14; 31.56; 26.94; 27.08; 30.69
SECONDARY
Satisfaction With Life Scale
17.25; 17.27; 17.08; 19.62; 19.40; 17.51
SECONDARY
Subjective Happiness Scale
16.45; 16.53; 16.29; 17.91; 17.36; 16.35
SECONDARY
Problematic and Risky Internet Use Screening Scale (PRIUSS-3)
4.79; 4.45; 4.42; 3.96; 3.97; 4.94

Summary

The central aim of this study is to test the efficacy of the Healthy Minds Program (HMP) app, an intervention designed to promote well-being. The investigators plan to conduct a randomized controlled trial (RCT) involving 1100 participants comparing 4-weeks of the HMP app with an active control (Psychoeducation [HMP without meditation practice]), and a waitlist control in a sample of United States adults with elevated depression symptoms.

Eligibility Criteria

Inclusion Criteria

  • Elevated PHQ-8 or PHQ-9 ≥ 5 at screening
  • Proficient in English
  • Able to provide informed consent
  • Have access to a smartphone that can download apps from Google Play or the Apple App Store
  • For payment purposes, must be a US citizen or a permanent US resident

Exclusion Criteria

  • Regular daily meditation practice for past 6 months or regular weekly meditation practice for past 12 months
  • Attended a meditation retreat or a yoga/body practice retreat with a significant meditation component
  • Previous use of Healthy Minds Program app
  • Current suicidal intent and/or high self-injury risk (determined from the interview)
  • Self-reported history of psychosis
  • Self-reported history of mania
  • Current psychopathology that interferes with study participation as assessed by interview
  • Living or traveling outside the US during the whole study participation period (trips outside US after the interview phase is not an exclusion)
  • Alcohol Use Disorders Identification Test (AUDIT) score ≥ 13 for women and AUDIT score ≥ 15 for men
  • Drug Use Disorders Identification Test (DUDIT) score ≥ 8 for women and men
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05183867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search